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Background: Only limited data are available on the blood phenylalanine (Phe) concentrations achieved in European patients
with phenylketonuria (PKU) on a low-Phe diet.
Objective: A survey was conducted to compare blood Phe control achieved in diet-treated patients with PKU of different age
groups in 10 European centres.
Methods: Centres experienced in the management of PKU from Belgium, Denmark, Germany, Italy, The Netherlands, Norway,
Poland, Spain, Turkey and the United Kingdom provided retrospective audit data of all patients with PKU treated by diet over a
1-year period. Standard questions were used to collect median data on blood Phe concentrations, percentage of blood Phe
concentrations below upper target reference ranges and frequency of blood Phe sampling.
Results: Data from 1921 patients on dietary management were included. Blood Phe concentrations were well controlled and
comparable across centres in the early years of life. The percentages of blood Phe concentrations meeting each centre’s local and
national target ranges were 88% in children aged up to 1 year, 74% for 1–10 years, 89% for 11–16 years and 65% for adults
(416 years). The frequency of home blood sampling, compared with local and national recommendations for monitoring Phe
concentrations, appeared to decline with age (from approximately 100% in infancy to 83% in teenagers and 55% in adults).
Conclusions: Although blood Phe control generally deteriorated with age, some improvement was observed in adolescent years
across the 10 European centres. The blood Phe control achieved seemed comparable in many of the European centres
irrespective of different dietary treatments or national policies.
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Introduction
Phenylketonuria (PKU) arises from mutations of the gene
coding for the enzyme phenylalanine (Phe) hydroxylase
(PAH), resulting in its deficiency. PAH is the major enzyme
responsible for the hydroxylation of Phe to tyrosine.
Untreated PKU leads to profound and irreversible mental
retardation, but treatment from birth with a Phe-restricted
diet prevents most of the adverse neuropsychological
sequelae of the disorder (Meli and Bianca, 2002). However,
the dietary management of PKU varies widely throughout
Europe (Ahring et al., 2009) and only limited data are
available comparing blood Phe control achieved among
diet-treated patients with PKU in different centres across
Europe. We compared retrospectively the blood Phe control
achieved in diet-treated patients with PKU of all age groups
in 10 European centres.
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Methods
Retrospective clinical audit data on blood Phe concentra-
tions were obtained using a predefined set of questions for
all patients with PKU treated with a diet who were regularly
reviewed at clinical centres experienced in the management
of PKU in Belgium, Denmark, Germany, Italy, The
Netherlands, Norway, Poland, Spain, Turkey and the United
Kingdom. The survey included patients treated with a diet
for at least 12 months beginning 1 July 2007 up to 1 July
2008 (in Turkey, because of a large patient population and
difficulties in assessment of data, results were based on
1 month of treatment of patients attending clinics).
Centres followed local or national age-defined recommen-
dations regarding target blood Phe concentrations (Supple-
mentary Table 1) and frequency of blood sampling (data not
shown). Centres in Belgium and Spain recommended that
blood samples be collected at the same (unspecified) time of
day, whereas other centres recommended sampling in the
morning after an overnight fast. Each centre used its routine
methodology for measuring blood Phe.
Eligible patients had PKU, were on dietary treatment, with
or without BH4 (tetrahydrobiopterin, sapropterin dihydro-
chloride, Kuvan) therapy and with or without large neutral
amino-acid (LNAA) supplements. Key exclusions were pa-
tients not on dietary treatment; following preconception
diet; pregnant; non-return of blood Phe samples; or lost to
follow-up. Ethical approval was required (and obtained) only
for the Turkish centre.
Data on each parameter (see Results) were initially
reported by each centre in the form of medians (with ranges
for median blood Phe concentrations (mmol/l) achieved;
Supplementary Tables 2–4). The medians of these medians
were then calculated and their interquartile ranges were used
as a measure of variability. No statistical analyses were
performed to compare results between groups; thus, com-
parative results reported are solely observational in nature.
Results
Patients
Overall, 1921 patients on dietary treatment met the inclu-
sion criteria; 115 patients in three centres received LNAA and
17 patients from Spain also received BH4 (Supplementary
Table 5). Principal reasons for exclusion were return to a
normal diet (n¼188); preconception or pregnancy (n¼40);
loss to follow-up; or failure to return blood Phe samples
(n¼ 143).
Blood Phe concentrations achieved
Blood Phe appeared to be well controlled up to 16 years of
age, as they were within each centres’ national or local target
ranges (Supplementary Tables 1 and 2). Annual median
blood Phe concentrations (Supplementary Table 3) were
similar between centres, except for Spain, where median
blood Phe concentrations wereo100 mmol/l for ageo1 year,
and Turkey, where median blood Phe was above the goal for
4–10 years. Overall, blood Phe concentrations appeared to
increase with age (Table 1). As suggested by the increasing
magnitudes of interquartile ranges, the variability of blood
Phe concentrations appeared to generally increase with
increasing age, except for the 1- to 3-year age group (Table 1).
In the three centres prescribing LNAA, annual median
blood Phe concentrations were 1297 mmol/l (Denmark),
876 mmol/l (Italy) and 1274 mmol/l (Norway) (Supplementary
Table 3). All these patients were adults, with median ages
of 33 (range 19–49), 31 (range 18–42) and 39 years (range
27–48), respectively.
Proportions of blood samples meeting guideline targets
The proportions of blood Phe samples that met target Phe
concentration ranges set by local or national PKU guidelines
(Table 1, Supplementary Table 3) appeared to decline for age
ranges up to 10 years, to improve during adolescence (11–16
years) (89%) and to decline again in adulthood (416 years).
In patients prescribed LNAA, the median percentage of blood
samples with Phe concentrations within treatment guide-
lines was reported to be 72% for Denmark and 100% for
Norway (data unavailable for Italy).
Frequency of returning blood Phe samples
Patients used a home blood Phe sampling system, except for
those treated at the Turkish centre, where home blood
samples were collected in the short term by a small number
of families if blood Phe control was unacceptable. Overall,
Table 1 Parameters related to the management of blood Phe
concentrations within 12 months in patients with PKU managed using













o1 175 (137–195) 88 (82–96) 102 (100–112)
1–3 230 (206–246) 74 (67–86) 100 (92–121)
4–10 287 (254–327) 74 (58–85) 92 (90–117)
11–16 465 (347–527) 89 (64–95) 83 (66–87)
Adult (416) 777 (604–855) 65 (44–88) 55 (51–75)
Data shown are medians (interquartile ranges) calculated from median values
for each parameter supplied by each centre over a period of 12 months
(2007–2008). Median blood Phe concentrations achieved for individual
centres are shown in Supplementary Tables 2–4.
aThe median percent of blood samples for home Phe sampling returned to
nine centres (excluding Turkey, which does not employ a home monitoring
system) during the study period. These data are expressed as a percentage of
the number of samples required by national guidelines.
bPercentages 4100% resulted when patients returned samples more
frequently than required by guidelines.
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the proportion of blood samples returned according to
guidelines was close to 100% for ages up to 3 years, but
then declined with increasing age (Table 1, Supplementary
Table 4), with little evidence of variability between centres,
as suggested by interquartile ranges (12–29%). The median
percentage of blood Phe samples returned according to
guidelines was low for patients on LNAA: 35% (Denmark),
3% (Italy) and 27% (Norway).
Discussion
Our data showed that despite the heterogeneity of local and
national PKU guidelines across European PKU centres, blood
Phe concentrations in patients with PKU appeared to be
generally comparable during the early years of life for most
of these 10 European PKU centres. Blood Phe concentrations
increased with age, consistent with other reports (Mundy
et al., 2002; Walter et al., 2002). Control in adults was similar
to that reported elsewhere, although blood Phe control
(according to local or national guidelines) appeared better
for adolescents than reported previously (Meli and Bianca,
2002; Mundy et al., 2002; Walter et al., 2002; Walter and
White, 2004). Increased availability of relatively palatable
liquid protein substitutes (MacDonald et al., 2006), an
increased range of low protein special food and better
patient education may have improved control in teenagers.
Blood Phe control, and the rate of returning of samples,
deteriorated markedly (and became more variable between
centres) by adulthood, despite the upper limit of target
ranges for blood Phe usually being higher than for younger
age groups. The apparent suboptimal blood Phe control for
most age groups at the Turkish centre was consistent with
previous findings (Gokmen Ozel et al., 2008). Moreover,
given our exclusion criteria, the blood Phe results reported
are likely to be from the most adherent and motivated
patients in this age group, who attended clinics and returned
blood samples.
Our survey was subject to limitations. Centres followed
different guidelines for the management of PKU. In addition,
we collected no data on dietary intake or adherence with
protein substitute (suboptimal dietary compliance known to
limit blood Phe control (Walter et al., 2002)), missed clinic
visits, social backgrounds, educational achievement, PKU
centres’ education policies or economic factors. Further-
more, this short-term, retrospective analysis could provide
only a snapshot of the quality of control of PKU at a given
time point. Finally, our exclusion of non-diet-managed
patients would favour the inclusion of younger patients,
who are more likely to be following the Phe-restricted diet.
It is important to document the degree of blood Phe
control achieved across different European centres, as the
management of PKU is constantly changing. In the future,
for example, the wider availability of the pharmaceutical
formulation of BH4 (sapropterin dihydrochloride, Kuvan),
when used in combination with a low-Phe diet, may
facilitate better blood Phe control in patients with the
BH4-sensitive phenotype of PKU. Nevertheless, the manage-
ment of adult patients remains challenging.
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